Skip to main content
Clinical Trials/NCT05777694
NCT05777694
Completed
Not Applicable

Investigation of the Effect of Needle Thickness on Postdural Puncture Headache: a Prospective Randomized Study

Bakirkoy Dr. Sadi Konuk Research and Training Hospital1 site in 1 country750 target enrollmentStarted: February 1, 2022Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Enrollment
750
Locations
1
Primary Endpoint
PDPH and spinal needle

Overview

Brief Summary

The aim of this study is to compare the effect of spinal needle type on postdural puncture headache in patients who will undergo cesarean section.

The main question[s] it aims to answer are:

[Does spinal needle thickness affect postdural puncture headache?]

[What is the response of patients who develop postdural puncture headache to treatment?] In cases accepting cesarean section operation under spinal anesthesia, different tables were used with spinal needles, and it will be questioned whether headache will develop in the first 15 days postoperatively. Postdural puncture headache after surgery will be described.

Detailed Description

Our study was designed as a prospective randomized study. Patients aged 20-50 years who accepted cesarean section under elective spinal anesthesia were included in the study. randomized into 3 groups with 250 patients in each group:

Group 1: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle ( Pencan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany) Group 2: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle ( Atraucan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany) Group 3: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle ( Pencan ® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany) Postdural puncture headache (PDPH) was evaluated by visiting patients who were discharged to the service after spinal anesthesia in the hospital for 24 hours, and by calling them within 15 days after discharge. Conservative and medical treatment was recommended for patients who developed PDPH, and the response of the patients to treatment was evaluated.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Masking Description

The prospective randomized study was randomized into 3 groups:

Group 1: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle ( Pencan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany) Group 2: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle ( Atraucan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany) Group 3: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle ( Pencan ® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)

Eligibility Criteria

Ages
20 Years to 50 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Pregnant women who accept spinal anesthesia and have no contraindications for spinal anesthesia Ages of 20-50 years ASA II-III

Exclusion Criteria

  • Pregnant women who do not accept spinal anesthesia and who are contraindicated for spinal anesthesia Morbid obesity(BMI\>40) Coagulopaty ASA 4 Clinically known local anesthetic allergy

Outcomes

Primary Outcomes

PDPH and spinal needle

Time Frame: postoperatively 15 days. The hospital was visited on the first day and information was obtained by calling in the following days. Patients with PDPH were evaluated as mild (1-3), moderate (4-7), severe (8-10) according to the Lybecker classification.

The primary aim of this study is to investigate the effect of needle type used on postdural puncture headache.

Secondary Outcomes

  • Treatment response of patients with PDPH(postoperatively 15 days, The hospital was visited on the first day and information was obtained by calling in the following days. Oral drugs used in the treatment and recommendations were noted.)

Investigators

Sponsor
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

Duygu Akyol

Principal Investigator

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Study Sites (1)

Loading locations...

Similar Trials